Holen Sie sich die Stockscreener-App
1.67
2.34%
-0.04
Handel nachbörslich:
1.67
Schlusskurs vom Vortag:
$1.71
Offen:
$1.7
24-Stunden-Volumen:
209.45K
Relative Volume:
0.89
Marktkapitalisierung:
$124.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.5335
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
-7.22%
1M Leistung:
-7.22%
6M Leistung:
-25.11%
1J Leistung:
+22.79%
1-Tages-Spanne:
$1.66
$1.70
1-Wochen-Bereich:
$1.655
$1.84
52-Wochen-Spanne:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
(302) 295-3800
Adresse
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Vergleichen Sie IKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.67 | 127.42M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
What high frequency data says about Inhibikase Therapeutics Inc.July 2025 Closing Moves & Fast Exit/Entry Strategy Plans - Newser
Can Inhibikase Therapeutics Inc. hit a new high this month2025 Top Decliners & Free Risk Controlled Daily Trade Plans - Newser
What are analysts’ price targets for Inhibikase Therapeutics Inc.Earnings Miss & Weekly Watchlist for Hot Stocks - خودرو بانک
Inhibikase Therapeutics Reports Q2 2025 Financials and Progress - MSN
Analyzing drawdowns of Inhibikase Therapeutics Inc. with statistical toolsTrade Volume Report & Real-Time Stock Price Movement Reports - Newser
Measuring Inhibikase Therapeutics Inc.’s beta against major indices2025 Major Catalysts & Community Verified Swing Trade Signals - Newser
What is the earnings history of Inhibikase Therapeutics Inc.M&A Rumor & Daily Technical Stock Forecast Reports - خودرو بانک
Applying Elliott Wave Theory to Inhibikase Therapeutics Inc.Market Trend Review & Real-Time Market Sentiment Reports - Newser
Using RSI to spot recovery in Inhibikase Therapeutics Inc.2025 Analyst Calls & AI Driven Price Predictions - Newser
Relative strength of Inhibikase Therapeutics Inc. in sector analysis2025 EndofYear Setup & High Accuracy Trade Alerts - Newser
What is the next catalyst for Inhibikase Therapeutics Inc.Earnings Performance Report & Weekly Watchlist for Consistent Profits - خودرو بانک
Sentiment Review: Can Inhibikase Therapeutics Inc. continue delivering strong returns2025 Dividend Review & Low Risk High Win Rate Picks - خودرو بانک
Is Inhibikase Therapeutics Inc. stock a smart retirement pickJuly 2025 Catalysts & Safe Entry Zone Tips - خودرو بانک
Is a relief rally coming for Inhibikase Therapeutics Inc. holdersInflation Watch & Verified Stock Trade Ideas - Newser
Should you hold or exit Inhibikase Therapeutics Inc. nowJuly 2025 Fed Impact & Community Shared Stock Ideas - Newser
Is Inhibikase Therapeutics Inc. subject to activist investor interest2025 Growth vs Value & Detailed Earnings Play Strategies - خودرو بانک
Using R and stats models for Inhibikase Therapeutics Inc. forecastingSwing Trade & Free Expert Verified Stock Movement Alerts - Newser
What’s the profit margin of Inhibikase Therapeutics Inc.July 2025 Gainers & AI Powered Market Entry Strategies - خودرو بانک
Published on: 2025-09-03 08:54:14 - Newser
Using portfolio simulators with Inhibikase Therapeutics Inc. includedCEO Change & Entry Point Strategy Guides - Newser
What earnings revisions data tells us about Inhibikase Therapeutics Inc.Quarterly Portfolio Report & Community Supported Trade Ideas - Newser
Will Inhibikase Therapeutics Inc. benefit from macro trendsJuly 2025 Review & Long Hold Capital Preservation Plans - Newser
Aug Sectors: What is the next catalyst for Inhibikase Therapeutics Inc.July 2025 Snapshot & Pattern Based Trade Signal System - خودرو بانک
Does Inhibikase Therapeutics Inc. outperform in volatile markets2025 Short Interest & AI Driven Price Predictions - خودرو بانک
Is Inhibikase Therapeutics Inc. affected by consumer sentimentEarnings Growth Summary & Safe Capital Allocation Plans - خودرو بانک
Is Inhibikase Therapeutics Inc. a stock for growth or value investorsJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - خودرو بانک
Reversal indicators forming on Inhibikase Therapeutics Inc. stock2025 Institutional Moves & Community Consensus Picks - Newser
Published on: 2025-09-01 22:20:55 - Newser
Is it time to cut losses on Inhibikase Therapeutics Inc.July 2025 PostEarnings & Weekly Watchlist for Hot Stocks - Newser
Is Inhibikase Therapeutics Inc. undervalued by DCF analysis2025 Technical Overview & Smart Swing Trading Techniques - خودرو بانک
Is Inhibikase Therapeutics Inc. forming bullish engulfing patternsWeekly Gains Summary & Fast Moving Market Watchlists - خودرو بانک
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | - openPR.com
Parkinson’s Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, - Barchart.com
Using Python tools to backtest Inhibikase Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Smart Swing Trading Techniques - Newser
Inhibikase Therapeutics (NASDAQ:IKT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Published on: 2025-08-31 22:05:17 - Newser
Ranking Inhibikase Therapeutics Inc. among high performing stocks via tools2025 Big Picture & Weekly High Return Opportunities - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):